Brief: Relay Therapeutics Announces Zovegalisib Granted Therapy Designation By FDA For Pik3ca-Mutant
03/02/2026 13:11
Feb 3 (Reuters) - Relay Therapeutics Inc RLAY.O: RELAY THERAPEUTICS ANNOUNCES ZOVEGALISIB GRANTED BREAKTHROUGH THERAPY DESIGNATION BY U.S. FDA FOR PIK3CA-MUTANT, HR+/HER2- ADVANCED BREAST CANCER Source text: ID:nGNX5Wy4tL Further company coverage: RLAY.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Relay Therapeutics
See all newsBrief: X-Chem Announces Phase 3 Milestone In Collaboration With Relay Therapeutics
Relay Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Relay Therapeutics Q2 revenue misses estimates on higher R&D expenses; net loss widens
Brief: Relay Therapeutics Q2 Net Income USD -83.707 Million Vs. IBES Estimate USD -74.2 Million
U.S. RESEARCH ROUNDUP- Alliant Energy, Prog Holdings, Travelers